Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2023-02-15
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
NCT00467870
Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)
NCT03687606
Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80
NCT00163566
Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate
NCT00555087
Steady-State Feedback Actions of Testosterone on Luteinizing Hormone Secretion in Young and Older Men
NCT00431197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
(1) Vital signs; (2) liver and kidney function; (3) blood routine; (4) electrocardiogram; (5) Adverse events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Shen Hai Long Group
Shen Hai Long Capsule
3 times/day (9 capsules/day) for 12 weeks
Sheng Jing Group
Sheng Jing Capsule
3 times/day (12 capsules/day) for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Shen Hai Long Capsule
3 times/day (9 capsules/day) for 12 weeks
Sheng Jing Capsule
3 times/day (12 capsules/day) for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients with mild to moderate asthenospermia, that is, at least two normative semen analyses indicated that 10%≤PR percentage \< 32% and the total number of PR sperm ranged from 5 million to 20 million;
3. At least two standard semen analyses indicated that sperm concentration ≥15×106 /ml; Sperm normal morphology rate ≥4%;
4. No other Chinese and Western drugs for the treatment of oligospermia, weak and malformed spermia have been taken in the past 3 months;
5. The subject voluntarily participates and signs the informed consent.
Exclusion Criteria
2. Genital tract infection: seminal plasmic elastase \> 1000ng/ml or leukocyte semen disease (peroxidase positive cell concentration in semen more than 1×10\^6/mL);
3. Erectile dysfunction, ejaculation disorders;
4. suffer from mental disorders, immune system diseases; Severe impairment of liver and kidney function (serum transaminase ≥2× upper limit of medical reference value, creatinine clearance ≤40ml/min or active stage of chronic kidney disease);
5. Patients with allergic history or constitution to therapeutic drugs;
6. Patients who have taken drugs affecting the study within 3 months, such as antitumor and antiepileptic drugs, etc.
22 Years
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongnan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yuanzhen Zhang
Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yuanzhen Zhang, Prof.
Role: PRINCIPAL_INVESTIGATOR
Wuhan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Shenhailong2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.